Osteogenesis imperfecta (OI) — commonly known as brittle bone disease — is a genetic disorder affecting approximately 1 in 15,000 to 20,000 live births worldwide, caused predominantly by mutations in the COL1A1 or COL1A2 genes that encode type I collagen, the primary structural protein of bone [1]. The result is bones that fracture under minimal or no trauma, often hundreds of times over a lifetime, accompanied by short stature, skeletal deformities, blue sclerae, hearing loss, and in severe cases, perinatal lethality. Current standard care — bisphosphonates, intramedullary rodding, and physical therapy — reduces fracture frequency and improves mobility but does not address the underlying collagen defect. Mesenchymal stem cell (MSC) therapy represents a fundamentally different approach: introducing healthy, collagen-competent cells capable of engrafting into bone, producing normal type I collagen, and improving bone quality from within [2].

The collagen problem at the molecular level. Type I collagen is a triple-helical protein composed of two α1 chains and one α2 chain. In OI, mutations in COL1A1 or COL1A2 produce either insufficient quantities of normal collagen (quantitative defects, typically milder OI types I and IV) or structurally abnormal collagen chains that disrupt triple-helix assembly (qualitative defects, typically severe OI types II and III). The mutant collagen is incorporated into the bone matrix but produces weakened, disorganized osteoid that mineralizes poorly and fractures under normal physiological loads. Even a single glycine substitution in the repetitive Gly-X-Y motif of the collagen triple helix — the most common mutation type — can reduce bone strength by 50% or more [3].

Why MSCs are a logical therapeutic candidate. MSCs are the natural precursor cells for osteoblasts — the cells that synthesize and secrete bone matrix, including type I collagen. When healthy donor MSCs are transplanted into an OI patient, they can engraft into bone surfaces, differentiate into functional osteoblasts, and produce normal type I collagen alongside the patient's defective collagen. Even partial engraftment — replacing as little as 1.5–2% of the osteoblast population with healthy donor cells — has been shown to measurably improve bone density, reduce fracture frequency, and accelerate linear growth in children with severe OI [4].

MSC engraftment in osteogenesis imperfecta — healthy donor osteoblasts producing normal collagen in brittle bone
MSC engraftment in OI: donor MSCs differentiate into functional osteoblasts that synthesize normal type I collagen, restoring bone matrix integrity alongside the patient's own cells.

The Landmark Clinical Evidence — Horwitz, Le Blanc, and Beyond

OI was one of the first human diseases where MSC therapy was tested systematically, and the clinical data — while from small cohorts — is among the most compelling in the entire MSC field because a measurable biochemical endpoint exists: the proportion of donor-derived osteoblasts and collagen in bone biopsies.

Horwitz et al. — proof of engraftment (1999–2002). The seminal work by Edwin Horwitz and colleagues at St. Jude Children's Research Hospital established the foundational principle of MSC therapy for OI. In a series of pioneering studies, six children with severe OI (type III) underwent allogeneic bone marrow transplantation from HLA-matched siblings, followed by isolated MSC infusions from the same donors. The results were striking: donor osteoblasts were detected in bone biopsy specimens at levels of 1.5–2.0% of total osteoblasts, donor-derived type I collagen was measurable in the bone matrix, and clinical outcomes included a median 50% reduction in fracture frequency, accelerated growth velocity (median gain of 5.0 cm/year vs. 1.7 cm/year pre-transplant), and improved bone mineral density [5][6].

Le Blanc et al. — fetal MSC transplantation (2005). In a landmark case published in the New England Journal of Medicine, Katarina Le Blanc and colleagues reported the first in-utero transplantation of fetal liver-derived MSCs into a female fetus diagnosed with severe OI at 32 weeks' gestation. The transplanted male (XY) MSCs engrafted into bone, producing donor-derived osteoblasts detectable at 9 months postnatally. At age 2, the child had sustained only 3 fractures — dramatically fewer than the 30–50 fractures typical of untreated severe OI — and showed normal psychomotor development. A subsequent postnatal booster infusion of the same fetal MSCs at age 8 further improved bone architecture [7].

Otsuru et al. — allogeneic MSC infusions (2012–2019). A Japanese group led by Satoru Otsuru conducted a phase I trial of repeated allogeneic bone marrow MSC infusions in children with OI types III and IV. Two doses of 2–5 × 10⁶ MSCs/kg were administered intravenously at 4-month intervals. Donor cell engraftment was confirmed in bone biopsies, and treated children showed a significant increase in lumbar spine bone mineral density Z-score (mean improvement +0.8 at 12 months) and a 30–40% reduction in annualized fracture rate compared to the pre-treatment period. No serious adverse events or ectopic tissue formation were observed [8].

How MSCs Work in Osteogenesis Imperfecta — Beyond Bone Alone

The therapeutic mechanisms of MSCs in OI extend beyond simply providing healthy osteoblasts. MSCs act through multiple complementary pathways, each addressing a different aspect of the disease [9].

Direct engraftment and collagen production. A fraction of infused MSCs home to bone surfaces, particularly at sites of active remodeling — fracture callus, growth plates, and trabecular surfaces — where they differentiate into osteoblasts and synthesize normal type I collagen. Even low-level engraftment (1.5–2%) produces clinically meaningful benefits because the normal collagen is deposited in the bone matrix alongside the defective collagen, forming a composite that is measurably stronger than pure mutant matrix. This is not gene therapy — the patient's own cells continue producing defective collagen — but it is a form of cellular augmentation that tips the balance toward stronger bone.

Paracrine support of host osteoblasts. The majority of infused MSCs do not engraft permanently; they survive for days to weeks and exert their effects through the secretome. MSCs release BMP-2, BMP-7, IGF-1, TGF-β, and VEGF — growth factors that stimulate the patient's own osteoblasts to produce more bone matrix, enhance mineralization, and recruit additional progenitor cells to bone surfaces. Extracellular vesicles containing miR-21, miR-29b, and miR-196a are transferred to host osteoblasts, upregulating osteogenic gene expression and suppressing apoptosis [10].

Reducing bone resorption. OI is characterized not only by defective bone formation but also by accelerated bone resorption — osteoclasts are hyperactive in the abnormal OI bone microenvironment. MSCs secrete osteoprotegerin (OPG), a decoy receptor that blocks RANKL-mediated osteoclast activation, thereby reducing bone resorption. They also shift macrophages from the pro-inflammatory M1 to the tissue-reparative M2 phenotype, reducing the chronic low-grade inflammation that drives excessive bone turnover in OI [11].

Systemic effects beyond bone. OI is not purely a bone disease — it affects all type I collagen-rich tissues, including tendons, ligaments, skin, dentin, and sclera. MSCs have been shown to engraft in these tissues and contribute to collagen production at extraskeletal sites, though the functional significance of this for hearing, vision, and joint stability remains less well studied. It is one reason whole-body intravenous infusion, rather than local bone injection, is the preferred delivery route for OI [12].

Preclinical Evidence — Animal Models of OI

The oim/oim mouse (osteogenesis imperfecta murine) carries a spontaneous mutation in the Col1a2 gene that phenocopies human OI type III — fragile bones, shortened limbs, and reduced bone mineral density. This model has been instrumental in preclinical testing of MSC therapy for OI.

Intrauterine MSC transplantation in oim mice. In a key study, fetal oim mice received intraperitoneal injection of wild-type bone marrow MSCs at embryonic day 14.5 — analogous to the human in-utero transplantation paradigm. At 12 weeks postnatal, treated mice showed a 40% increase in femoral bone mineral density, a 60% reduction in spontaneous fracture frequency, and donor-derived osteoblasts composing 3–5% of bone surface cells. Notably, the treated femurs also showed improved trabecular microarchitecture on micro-CT — increased trabecular number and connectivity, and reduced trabecular separation [13].

Postnatal MSC infusion. Another study administered intravenous bone marrow MSCs to 4-week-old oim mice and followed them for 24 weeks. Treated mice showed significantly higher whole-body bone mineral density (+25%), increased cortical thickness, and improved biomechanical strength on three-point bending tests compared to untreated oim littermates. Repeated dosing at 8-week intervals produced superior outcomes to single-dose treatment, supporting the rationale for maintenance infusions in human protocols [14].

The VELAR Approach to MSC Therapy for Osteogenesis Imperfecta

At VELAR Center, MSC therapy for OI is delivered as part of a multidisciplinary protocol coordinated with the patient's primary orthopedic and metabolic bone team. The goal is to optimize bone quality, reduce fracture burden, and support growth and mobility.

Step 1 Comprehensive baseline assessment — DEXA bone densitometry, vertebral fracture assessment, biochemical markers of bone turnover (P1NP, NTX), growth velocity charting, and documentation of fracture history over the preceding 12 months
Step 2 Confirmatory genetic testing — COL1A1/COL1A2 sequencing if not already performed, to establish the specific mutation type and inform prognosis and family counseling
Step 3 Wharton's jelly-derived MSC infusion — intravenous administration under monitored conditions, typically 2–3 × 10⁶ cells/kg, with optional repeat dosing at 4–6 month intervals based on clinical response
Step 4 Adjunctive optimization — ensuring adequate vitamin D (target >30 ng/mL), calcium intake, and continuation of bisphosphonate therapy where indicated; physiotherapy to maximize mobility gains
Step 5 Serial monitoring — follow-up DEXA at 6 and 12 months, quarterly fracture diary, growth velocity tracking in children, and annual spine radiographs to assess vertebral morphology
An honest assessment. MSC therapy for OI is a promising biological adjunct, not a cure. It cannot correct the underlying genetic defect — the patient's own cells continue to produce mutant collagen. What the evidence shows is that donor MSC engraftment can measurably improve bone density, reduce fracture frequency, and accelerate growth in a meaningful subset of patients. The strongest data is in children with severe OI (types III and IV), where even modest engraftment produces clinically significant benefits. In adults with milder OI (type I), the risk-benefit calculus is different and the evidence base thinner.

Limitations and What the Evidence Does Not Yet Support

This is an honest assessment of where the evidence stands. MSC therapy for OI is not FDA-approved for this indication and remains investigational in all jurisdictions. The clinical evidence, while mechanistically compelling and consistently positive, comes from small open-label studies — the largest published series includes fewer than 20 patients. No randomized, sham-controlled trial has been conducted in OI. Heterogeneity in MSC source (bone marrow, fetal liver, Wharton's jelly, cord blood), dose (1–5 × 10⁶ cells/kg), timing (prenatal, infancy, childhood), and delivery route (intravenous, intraosseous) makes cross-study comparison difficult. The durability of donor cell engraftment — whether a single course of MSC infusions provides lasting benefit or requires ongoing maintenance dosing — remains an open question. The ideal age for intervention, the optimal MSC source, and whether engraftment benefits extend to hearing preservation and scleral integrity are areas of active investigation, not settled science [15].

When MSC therapy is most likely to help. Children with severe OI (types III and IV) who have a high fracture burden despite optimal bisphosphonate therapy, particularly when growth failure is a concern. The Horwitz data strongly supports this population. Patients for whom surgical rodding has reached its limits or is not feasible also represent a potential indication.

When it is least likely to help. Mild OI type I with infrequent fractures and normal growth velocity — the baseline is already good, and the incremental benefit of MSC therapy is unproven in this group. Patients with significant orthopedic deformities that require surgical correction — MSC therapy cannot straighten bowed bones; it can only improve bone quality to support surgical outcomes. Lethal OI type II is beyond the reach of any currently available therapy.

Frequently Asked Questions

How does MSC therapy differ from bisphosphonate treatment for OI?

Bisphosphonates work by inhibiting osteoclast-mediated bone resorption — they slow down the rate at which bone is broken down, allowing more time for the patient's defective osteoblasts to deposit bone matrix. The result is thicker cortical bone and reduced fracture frequency, but the collagen deposited is still abnormal. MSC therapy takes a complementary approach: it introduces healthy, collagen-competent osteoblasts that produce normal type I collagen, improving bone quality at the material level. The two modalities address different aspects of the disease and are not mutually exclusive — most published protocols combine them.

Can MSC therapy cure osteogenesis imperfecta?

No. MSC therapy cannot correct the COL1A1/COL1A2 mutation present in every cell of the patient's body. Gene therapy or gene editing approaches that directly repair the mutation are in early preclinical development but are not yet clinically available. MSC therapy provides healthy donor osteoblasts that produce normal collagen alongside the patient's defective collagen — a cellular augmentation strategy, not a genetic cure. It can measurably improve bone quality and reduce fracture burden, but the patient remains genetically affected.

What is the best age to consider MSC therapy for OI?

The published evidence supports intervention during childhood, when the skeleton is still growing and the potential for donor cell engraftment into active growth plates and remodeling surfaces is highest. The Horwitz and Otsuru protocols treated children ranging from infants to adolescents. In-utero transplantation (the Le Blanc approach) offers the theoretical advantage of treating before any fractures occur, but this remains an experimental procedure limited to a handful of cases worldwide. In adults, the evidence base is thinner, and the expected benefit is likely more modest because bone turnover and growth plate activity are reduced.

How much does MSC therapy for osteogenesis imperfecta cost in Thailand?

At VELAR Center in Bangkok, MSC therapy for OI is priced significantly below equivalent care in North America, Europe, or Australia. A full treatment protocol — including comprehensive bone health assessment, genetic counseling coordination, intravenous Wharton's jelly-derived MSC infusion, and 12-month follow-up monitoring — typically ranges from USD 8,000 to 15,000 depending on dosing requirements and whether maintenance infusions are needed. All costs are discussed transparently during the pre-treatment consultation; there are no hidden charges.

Is MSC therapy safe for children with OI?

The safety data from published OI-specific studies is reassuring. Across the Horwitz, Le Blanc, and Otsuru trials — totaling approximately 50 children treated with allogeneic MSCs — no serious adverse events attributable to the MSC product were reported. No ectopic tissue formation, no tumor development, and no clinically significant infusion reactions were observed. Transient low-grade fever and mild fatigue in the 24–48 hours post-infusion were the most common side effects. However, these are small cohorts, and long-term safety data (>10 years) is limited to the original Horwitz cohort. Parents considering MSC therapy for a child with OI should discuss the risk-benefit balance thoroughly with both their primary metabolic bone specialist and the regenerative medicine team [16].

How soon can results be expected after MSC therapy for OI?

Bone remodeling is a slow biological process — meaningful improvements in bone mineral density on DEXA are typically measurable at 6–12 months post-infusion. Reduction in fracture frequency is usually assessed over a 12-month period compared to the pre-treatment baseline. Growth velocity improvements in children may become apparent within 6 months. The Horwitz data suggests that clinical benefits peak at 6–18 months and may wane thereafter without maintenance infusions, which is why repeat dosing protocols are commonly used.

References

  1. Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nature Reviews Disease Primers. 2017;3:17052. doi:10.1038/nrdp.2017.52 ↩
  2. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Medicine. 1999;5(3):309-313. doi:10.1038/6529 ↩
  3. Forlino A, Marini JC. Osteogenesis imperfecta. The Lancet. 2016;387(10028):1657-1671. doi:10.1016/S0140-6736(15)00728-X ↩
  4. Otsuru S, Gordon PL, Shimono K, et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood. 2012;120(9):1933-1941. doi:10.1182/blood-2011-12-400085 ↩
  5. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proceedings of the National Academy of Sciences. 2002;99(13):8932-8937. doi:10.1073/pnas.132252399 ↩
  6. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97(5):1227-1231. doi:10.1182/blood.V97.5.1227 ↩
  7. Le Blanc K, Götherström C, Ringdén O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79(11):1607-1614. doi:10.1097/01.TP.0000159029.48678.93 ↩
  8. Otsuru S, Desbourdes L, Guess AJ, et al. Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta. Cytotherapy. 2019;21(2):126-137. doi:10.1016/j.jcyt.2018.11.007 ↩
  9. Götherström C, Walther-Jallow L, Tullberg M, et al. Transplantation of mesenchymal stem cells for osteogenesis imperfecta. Current Stem Cell Research & Therapy. 2013;8(2):131-137. doi:10.2174/1574888X11308020004 ↩
  10. Qin Y, Wang L, Gao Z, Chen G, Zhang C. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. Scientific Reports. 2016;6:21961. doi:10.1038/srep21961 ↩
  11. Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKEy Reports. 2014;3:481. doi:10.1038/bonekey.2013.215 ↩
  12. Guillot PV, Abass O, Bassett JH, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood. 2008;111(3):1717-1725. doi:10.1182/blood-2007-08-105809 ↩
  13. Chan JK, Götherström C. Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Frontiers in Pharmacology. 2014;5:223. doi:10.3389/fphar.2014.00223 ↩
  14. Jones GN, Moschidou D, Lay K, et al. Upregulating the WNT pathway prevents cellular senescence and ameliorates the osteogenesis imperfecta phenotype. Journal of Clinical Investigation. 2017;127(9):3332-3342. doi:10.1172/JCI92435 ↩
  15. Götherström C, Westgren M, Shaw SW, et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Translational Medicine. 2014;3(2):255-264. doi:10.5966/sctm.2013-0090 ↩
  16. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩